SCHEMBL3849564

SCHEMBL3849564

COc1ccc(Cn2cc(C[C@H](N)C(=O)OC#N)c3ccccc32)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.53
CHRNA7 P36544 1/20 0.53
CHRNA4 P43681 1/20 0.53
HTR6 P50406 1/20 0.53
CHRM1 P11229 1/20 0.52
ADAM17 P78536 3/20 0.50
MMP2 P08253 1/20 0.50
MMP13 P45452 1/20 0.50
MMP14 P50281 1/20 0.50
KMT2A Q03164 1/20 0.49
PLA2G2A P14555 2/20 0.48
LMNA P02545 2/20 0.46
HTT P42858 1/20 0.46
AHR P35869 1/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HDAC10 Q969S8 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3853673 0.90 KMT2A (0.51) HTR6ADAM17KMT2ALMNAHTT
SCHEMBL3848330 0.89 MAPT (0.49) ADAM17KMT2APLA2G2ALMNAPOLB
SCHEMBL3849188 0.89 CHRNB2 (0.58) CHRNB2CHRNA7CHRNA4HTR6CHRM1
SCHEMBL3851327 0.88 KMT2A (0.52) CHRNB2CHRNA7CHRNA4HTR6ADAM17
SCHEMBL3855721 0.88 ALDH1A1 (0.50) ADAM17KMT2ALMNAHTTPOLB
SCHEMBL3848663 0.88 CHRNB2 (0.57) CHRNB2CHRNA7CHRNA4HTR6CHRM1
SCHEMBL3849200 0.85 TP53 (0.48) CHRNB2CHRNA7CHRNA4KMT2APOLB
SCHEMBL3849560 0.80 ADAM17 (0.63) CHRNB2CHRNA7CHRNA4HTR6CHRM1
SCHEMBL3849568 0.80 ADAM17 (0.63) CHRNB2CHRNA7CHRNA4HTR6CHRM1
SCHEMBL9584105 0.80 KMT2A (0.65) CHRNB2CHRNA7CHRNA4HTR6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576222-B2 N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease WYETH (US) 2009-08-18 US disclosed
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase WYETH (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase ADAM17, TPSAB1, ADAM10 CHRNB2 3141/4885CHRNA7 2576/4885CHRNA4 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.